Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells

OBJECTIVES: Interleukin (IL)-17 signalling has been shown to be a key regulator of disease in ankylosing spondylitis (AS) with several IL-17 blockers currently clinically approved. Despite this, the role of IL-17 in bone pathology is poorly understood. This study aimed to investigate IL-17 signallin...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:RMD Open
Huvudupphovsmän: Shah, Mittal, Maroof, Asher, Gikas, Panos, Mittal, Gayatri, Keen, Richard, Baeten, Dominique, Shaw, Stevan, Roberts, Scott J
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2020
Ämnen:
Spondyloarthritis
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7722278/
https://ncbi.nlm.nih.gov/pubmed/32723833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2020-001306
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk